Joseph Catanzaro
Stock Analyst at Mizuho
(3.88)
# 629
Out of 5,149 analysts
105
Total ratings
46.51%
Success rate
12.23%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics | Initiates: Outperform | $26 | $14.01 | +85.65% | 1 | Mar 2, 2026 | |
| TNGX Tango Therapeutics | Initiates: Outperform | $19 | $11.37 | +67.11% | 2 | Feb 23, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $35 | $15.22 | +129.96% | 5 | Jan 29, 2026 | |
| IBRX ImmunityBio | Maintains: Overweight | $5 → $7 | $10.16 | -31.10% | 6 | Jan 20, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $6.5 → $10 | $5.11 | +95.69% | 6 | Jan 20, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $90 → $143 | $100.28 | +42.60% | 4 | Jan 13, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $17.18 | +127.01% | 1 | Dec 18, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $51 | $7.41 | +588.26% | 1 | Dec 18, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Neutral | $18 | $17.42 | +3.33% | 1 | Dec 18, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $53 | $40.51 | +30.83% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $120 | $87.49 | +37.16% | 2 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $29.14 | +64.72% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $105 | $67.15 | +56.37% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $3.77 | +59.36% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $11.85 | +279.75% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $146.33 | -24.83% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $40.79 | -6.84% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $13.57 | +10.54% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $69.07 | -23.27% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $1.87 | +436.19% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.29 | +1,372.87% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $9.60 | +97.92% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.33 | +545.16% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $12.75 | +182.35% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $10.30 | +288.54% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $10.83 | +38.50% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $2.23 | +101.79% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.58 | +1,798.73% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.14 | +1,662.11% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $2.67 | -34.46% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $23.95 | -16.49% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.55 | -41.18% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $28.59 | +599.55% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $17.00 | +105.88% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.34 | +4,377.61% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.31 | +679.22% | 3 | Apr 7, 2020 |
Eikon Therapeutics
Mar 2, 2026
Initiates: Outperform
Price Target: $26
Current: $14.01
Upside: +85.65%
Tango Therapeutics
Feb 23, 2026
Initiates: Outperform
Price Target: $19
Current: $11.37
Upside: +67.11%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $32 → $35
Current: $15.22
Upside: +129.96%
ImmunityBio
Jan 20, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $10.16
Upside: -31.10%
CytomX Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $6.5 → $10
Current: $5.11
Upside: +95.69%
Revolution Medicines
Jan 13, 2026
Maintains: Outperform
Price Target: $90 → $143
Current: $100.28
Upside: +42.60%
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $17.18
Upside: +127.01%
Upstream Bio
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $7.41
Upside: +588.26%
Bicara Therapeutics
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $17.42
Upside: +3.33%
Spyre Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $40.51
Upside: +30.83%
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $87.49
Upside: +37.16%
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $29.14
Upside: +64.72%
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $67.15
Upside: +56.37%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $3.77
Upside: +59.36%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $11.85
Upside: +279.75%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $146.33
Upside: -24.83%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $40.79
Upside: -6.84%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $13.57
Upside: +10.54%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $69.07
Upside: -23.27%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $1.87
Upside: +436.19%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.29
Upside: +1,372.87%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $9.60
Upside: +97.92%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.33
Upside: +545.16%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $12.75
Upside: +182.35%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $10.30
Upside: +288.54%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $10.83
Upside: +38.50%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $2.23
Upside: +101.79%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.58
Upside: +1,798.73%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.14
Upside: +1,662.11%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $2.67
Upside: -34.46%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $23.95
Upside: -16.49%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.55
Upside: -41.18%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $28.59
Upside: +599.55%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $17.00
Upside: +105.88%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.34
Upside: +4,377.61%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.31
Upside: +679.22%